Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Breast Cancer Stage IV: early-phase trial registry

6 of 11 indexed Breast Cancer Stage IV trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,577 of 28,707 conditions by registered trial count.

11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count

Breast Cancer Stage IV: 11 US clinical trials tracked, 6 recruiting.

Breast Cancer Stage IV is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 5 of these trials.

Enrollment posture brief

Registry condition breast-cancer-stage-iv

OPEN 6 | RECR 55% | LATE 0 | EARLY 8 | RANK #1577 | SPON 5

Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)

Acute Pancreatitis81.8%Breast Cancer Stage IV (this)55%Acute Stroke45.5%Acquired Brain Injury36.4%Acute Lung Injury9.1%
Open-enrollment share among volume-matched conditions near Breast Cancer Stage IV

Breast Cancer Stage IV lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer Stage IV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer Stage IV is recruiting above its size-band peers.

    6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Breast Cancer Stage IV research.

    Memorial Sloan Kettering Cancer Center accounts for 5 of 11 trials (45.5%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Breast Cancer Stage IV trials plan to enrol fewer than 100 people.

    Median target enrolment is 30 among the 11 trials that report a genuine target (sentinel values excluded). 10 of those (90.9%) plan for fewer than 100 participants.

  4. Breast Cancer Stage IV research is mostly interventional.

    8 interventional and 3 observational studies make up this index (72.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 24

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 2 86 participants

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

University of California, Davis

NCT06268665

RECRUITING Phase 2 60 participants

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Memorial Sloan Kettering Cancer Center

NCT07459673

RECRUITING Phase 1 48 participants

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

MBQ Pharma

NCT06075810

RECRUITING Phase 1 30 participants

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT06246968

RECRUITING Phase 1 28 participants

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT06678269

RECRUITING Phase 1 24 participants

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

General Oncology

NCT04150042

ACTIVE NOT RECRUITING 125 participants

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

Medical College of Wisconsin

NCT06234488

ACTIVE NOT RECRUITING 23 participants

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

Memorial Sloan Kettering Cancer Center

NCT05036252

ACTIVE NOT RECRUITING Phase 2 15 participants

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT05090358

ACTIVE NOT RECRUITING Phase 2 5 participants

Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer

Baylor Breast Care Center

NCT03324425

COMPLETED 68 participants

Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer

Indiana University School of Medicine

NCT00393341

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 4

Named interventions

Most-linked intervention names on Breast Cancer Stage IV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Simvastatin 80mg Drug
1 trials
Canagliflozin Drug
1 trials
Low Carbohydrate Diet Dietary supplement
1 trials
Ketogenic Diet Dietary supplement
1 trials
Cardiopulmonary Exercise Test Diagnostic test
1 trials
MBQ-167 Drug
1 trials
Tart Cherry Juice Drug
1 trials
Alpelisib Drug
1 trials

US sites by state

Facility locations filed on Breast Cancer Stage IV trials. A trial with sites in several states counts in each.

New York 7 trials
New Jersey 4 trials
California 3 trials
Tennessee 2 trials
Ohio 2 trials
Massachusetts 2 trials
Florida 2 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Breast Cancer Stage IV page

11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer Stage IV condition card totals 11 registered trials; most-linked intervention Simvastatin 80mg; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.